Clinical Trials Logo

Filter by:
NCT ID: NCT05234437 Terminated - Melanoma Clinical Trials

A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma

Start date: March 9, 2022
Phase: Phase 2
Study type: Interventional

A phase IIb, multicentre, open label study to evaluate the effectiveness, safety, and tolerability of intratumoural tigilanol tiglate in adult participants with Stage IIIB to IV M1c melanoma

NCT ID: NCT05232864 Terminated - Lupus Nephritis Clinical Trials

Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis

Start date: August 22, 2022
Phase: Phase 3
Study type: Interventional

The purpose is to provide treatment with secukinumab delivered subcutaneously (s.c.) via pre-filled syringe (PFS) for participants who complete study treatment until the Week 104 of the core study CAIN457Q12301 and to obtain long term efficacy, safety and tolerability data

NCT ID: NCT05220293 Terminated - Clinical trials for Chronic Rhinosinusitis (Diagnosis)

Treatment of Eosinophilic Chronic Rhinosinusitis Utilizing Betamethasone Dipropionate Nasal Cream

OT-007
Start date: February 23, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, single dose, pilot study, to assess the efficacy and safety of Betamethasone Dipropionate Nasal Cream 0.0644% (equivalent to 0.05% Betamethasone) for the treatment of eosinophilic Chronic Rhinosinusitis (eCRS).

NCT ID: NCT05205161 Terminated - Clinical trials for Non-Hodgkin Lymphoma

A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma

Start date: July 5, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates the safety, tolerability, PK, and preliminary efficacy of AZD0466 as monotherapy or in combination with other anticancer agents in patients with advanced NHL

NCT ID: NCT05188664 Terminated - Clinical trials for Advanced Solid Tumor

Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Start date: May 10, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM- 302 in Combination with Toripalimab in Patients with Advanced Solid Tumors

NCT ID: NCT05154890 Terminated - Clinical trials for Homocystinuria Due to Cystathionine Beta-Synthase Deficiency

A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency

Start date: May 13, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of pegtarviliase in approximately 36 subjects with homocystinuria due to CBS deficiency.

NCT ID: NCT05129280 Terminated - Solid Tumors Clinical Trials

A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors

Start date: January 25, 2022
Phase: Phase 1
Study type: Interventional

This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy dose-escalation and dose expansion study of RO7444973.The aim of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of RO7444973 in participants with unresectable and/or metastatic melanoma-associated antigen A4 (MAGE-A4)-positive, solid tumors, carrying the HLA-A*02:01 allele.

NCT ID: NCT05125068 Terminated - IgA Nephropathy Clinical Trials

Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

Start date: March 21, 2022
Phase: Phase 2
Study type: Interventional

This is a phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of screening.

NCT ID: NCT05116046 Terminated - Achondroplasia Clinical Trials

Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia

Start date: December 24, 2021
Phase: Phase 2
Study type: Interventional

All participants who completed the prior study to assess long-term safety, tolerability, pharmacokinetics and efficacy, and in the opinion of the investigator, continue to have a positive risk:benefit profile, will be offered to enroll in this open-label extension (OLE) study for up to an additional 24 months of treatment. Approximately 63 participants will be offered to continue at the previously received dose of Recifercept either Low Dose Medium Dose High Dose or at the therapeutic dose once it is identified. Participants will attend the clinic monthly for 24 months. Assessments include safety, blood sampling, physical examination, vital signs, anthropometric body measurements & patient/caregiver quality of life questionnaires.

NCT ID: NCT05109650 Terminated - Clinical trials for Advanced Solid Tumour

Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients

Start date: November 15, 2021
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, Phase 1 dose-escalation study of BAT6026, an OX40 monoclonal antibody, combined with the anti-PD-1 IgG4 monoclonal antibody BAT1308 in subjects with advanced solid tumours. After a screening period of up to 28 days, qualified subjects will be enrolled to receive their assigned dose regimen until disease progression or intolerable toxicity, withdrawal of consent, per Investigator decision, or end of study, whichever occurs first. The maximum treatment duration is 1 year. Subjects who remain on treatment in the absence of disease progression for more than 1 year may continue to receive study drug for the next cycle at the maximum of 2 years.